AR113823A1 - INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION, WITHOUT PAIN, EDEMA OR SIDE EFFECTS, AND A METHOD TO PREPARE THE SAME - Google Patents
INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION, WITHOUT PAIN, EDEMA OR SIDE EFFECTS, AND A METHOD TO PREPARE THE SAMEInfo
- Publication number
- AR113823A1 AR113823A1 ARP180103191A ARP180103191A AR113823A1 AR 113823 A1 AR113823 A1 AR 113823A1 AR P180103191 A ARP180103191 A AR P180103191A AR P180103191 A ARP180103191 A AR P180103191A AR 113823 A1 AR113823 A1 AR 113823A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- side effects
- edema
- localized fat
- composition
- Prior art date
Links
Abstract
La presente se relaciona con una composición para reducir grasa localizada sin dolor, edema ni efectos secundarios, y con un método para preparar la misma. Más específicamente, la presente se relaciona con una composición que comprende ácido glicocólico (o una sal del mismo) o ácido taurocólico (o una sal del mismo) y fosfatidilcolina (PPC) en una proporción de mezcla particular para reducir grasa localizada sin efectos secundarios tales como dolor, edema, necrosis de células musculares, fibroblastos y células del endotelio vascular distintas de los adipocitos, anestesia de los sitios de administración, hinchamiento extenso, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, daño nervioso, y disfagia, y con un método para preparar la misma. Se conoce que la preparación inyectable simple de DCA o preparación inyectable PPC en la cual se mezcla DCA como un agente solubilizante, que son las preparaciones inyectables convencionales para reducir grasa localizada, están acompañadas de dichos efectos secundarios tales como dolor, anestesia, hinchamiento extenso, edema localizado, eritema, endurecimiento, parestesia, nódulo, prurito, sensación de ardor, disfagia y lo similar debido a necrosis de células causada inevitablemente por la lisis de no sólo adipocitos sino también fibroblastos, células del endotelio vascular y células de músculo esquelético. De ese modo los pacientes se han estado quejando de dolor, malestar y ansiedad, con bajo cumplimiento. Por otra parte, la composición inyectable para reducir grasa localizada de acuerdo con la presente es una formulación segura y estable, realiza la lisis selectiva de adipocitos y tiene un excelente efecto en la inducción de apoptosis de adipocitos, de modo que es una excelente composición que mejora el cumplimiento y calidad de vida del paciente sin los efectos secundarios mencionados anteriormente.The present relates to a composition for reducing localized fat without pain, edema or side effects, and a method for preparing the same. More specifically, the present relates to a composition comprising glycocholic acid (or a salt thereof) or taurocholic acid (or a salt thereof) and phosphatidylcholine (PPC) in a particular mixing ratio to reduce localized fat without such side effects. such as pain, edema, necrosis of muscle cells, fibroblasts, and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, hardening, paresthesia, nodule, pruritus, burning sensation, nerve damage, and dysphagia , and with a method to prepare it. It is known that the simple injectable preparation of DCA or injectable preparation PPC in which DCA is mixed as a solubilizing agent, which are the conventional injectable preparations for reducing localized fat, are accompanied by such side effects such as pain, anesthesia, extensive swelling, localized edema, erythema, hardening, paraesthesia, nodule, pruritus, burning sensation, dysphagia and the like due to cell necrosis inevitably caused by the lysis of not only adipocytes but also fibroblasts, vascular endothelial cells, and skeletal muscle cells. Thus, patients have been complaining of pain, discomfort and anxiety, with low compliance. On the other hand, the injectable composition for reducing localized fat according to the present is a safe and stable formulation, performs the selective lysis of adipocytes, and has an excellent effect on the induction of adipocyte apoptosis, so that it is an excellent composition that improves patient compliance and quality of life without the aforementioned side effects.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170146264 | 2017-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113823A1 true AR113823A1 (en) | 2020-06-17 |
Family
ID=67702236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103191A AR113823A1 (en) | 2017-11-03 | 2018-11-02 | INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION, WITHOUT PAIN, EDEMA OR SIDE EFFECTS, AND A METHOD TO PREPARE THE SAME |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR113823A1 (en) |
| TW (1) | TW201922261A (en) |
-
2018
- 2018-11-02 AR ARP180103191A patent/AR113823A1/en unknown
- 2018-11-02 TW TW107138940A patent/TW201922261A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201922261A (en) | 2019-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004317A2 (en) | Injectable composition for localized fat reduction, without pain, edema or side effects, and method to prepare it. | |
| MX2020012595A (en) | Topical pharmaceutical compositions. | |
| AR093217A1 (en) | IMPROVED ANTAGONIST ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND USES OF THE SAME | |
| BR112021002069A2 (en) | Composition for hair treatment, methods and uses. | |
| CO2017006032A2 (en) | Methods to treat calcification of tissues | |
| CL2019000249A1 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof. | |
| CL2019000245A1 (en) | Moduladores nmda espiro-lactam and methods of use thereof. | |
| CL2019000247A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
| CL2019000246A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
| MX2014008284A (en) | Delayed-release formulation for reducing the frequency of urination and method of use thereof. | |
| CL2019002362A1 (en) | Low viscosity, high concentration evolocumab formulations and methods of making them. | |
| Dohnert et al. | Study of the effectiveness of interferential current as compared to transcutaneous electrical nerve stimulation in reducing chronic low back pain | |
| BR112021024117A2 (en) | Substituted pyrazol-pyrazines and their use as glun2b receptor modulators | |
| RU2016129193A (en) | COMPOSITIONS BASED ON BERBERIN AND THEIR APPLICATION | |
| Aguilera et al. | Successful treatment of calcium hydroxylapatite nodules with intralesional 5-fluorouracil, dexamethasone, and triamcinolone | |
| PH12015502497A1 (en) | Adhesion preventing material | |
| MX2016014230A (en) | Foods, systems, methods, and kits for providing electrolyte replacement. | |
| AR113823A1 (en) | INJECTABLE COMPOSITION FOR LOCALIZED FAT REDUCTION, WITHOUT PAIN, EDEMA OR SIDE EFFECTS, AND A METHOD TO PREPARE THE SAME | |
| EA201992759A1 (en) | ASSOCIATION INCLUDING OXYGEN AND HYALURONIC ACID, FOR LOCAL VAGINAL USE | |
| Schianchi | A new technique to treat facet joint pain with pulsed radiofrequency | |
| JOP20200031A1 (en) | Methods of treatment of osteoarthritis with transdermal cannabidiol gel | |
| Andrade et al. | Use of iontophoresis or phonophoresis for delivering onabotulinumtoxinA in the treatment of palmar hyperidrosis: a report on four cases | |
| MX2021000037A (en) | NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES. | |
| MX2020005921A (en) | Formulations and methods for vaginal delivery of antiprogestins. | |
| MX2023008804A (en) | Liquid formulation of protein and methods of preparing the same. |